Previous 10 | Next 10 |
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announces the launch of Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets, a therapeutic ...
Dr. Reddy's ( NYSE: RDY ) had declared INR 30.00/share annual dividend . Payable Aug. 2; for shareholders of record July 11; ex-div July 8. See RDY Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Dr. Reddy's goes ex-dividend t...
Dr. Reddy's Laboratories said its unit Aurigene, and EQRx are collaborating to develop drug candidates for cancer and immune-inflammatory diseases. Under the agreement, Aurigene will use its small molecule drug discovery platform and will lead drug discover...
The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory diseases and improve global access to innovative medicines. Unde...
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today declared that it had agreed to sell its hospital goods to Dr. Reddy’s Laboratories SA, a division of Dr. Reddy...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has acquired a portfolio of branded and generic injectable products from Deer Par...
Eton Pharmaceuticals (NASDAQ:ETON) has announced the sale of its hospital products to Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories (NYSE:RDY), for up to $50M. Pursuant to the deal, Dr Reddy's (RDY) took over Eton's rights and interests in Biorphen, Rezipres and Cystei...
Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 million Going forward, Eton’s commercial portfolio will exclusively focus on products that treat rare diseases Eton’s royalty portfolio is no...
Dr. Reddy's Laboratories (NYSE:RDY) launched its sorafenib tablets, a generic of Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) kidney/liver/thyroid cancer drug Nexavar (sorafenib), in the U.S. following the approval by the U.S. Food and Drug Administration (FDA). Dr. Reddy's sorafenib tablet...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Dr. Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic eq...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...